Information Provided By: 
Fly News Breaks for November 12, 2019
KDMN
Nov 12, 2019 | 07:18 EDT
Cantor Fitzgerald analyst Eliana Merle raised her price target for Kadmon Holdings to $10 from $8 and reiterates an Overweight rating on the shares. Interim data from KD025 in the chronic graft-versus-host disease pivotal study well exceeded the statistical bar needed for filing, Merle tells investors in a research note. She thinks this is a "robust data update on both efficacy and safety," and supportive of U.S. approval and a meaningful commercial opportunity.
News For KDMN From the Last 2 Days
There are no results for your query KDMN
